RYTM - Rhythm Pharmaceuticals appoints Garfield as Chief Scientific Officer
2024-07-08 13:35:43 ET
More on Rhythm Pharmaceuticals
- Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
- Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript
- Rhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93M
- Rhythm Pharmaceuticals Q1 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals